HAWAII BIOTECH, INC.

Basic Information

650 IWILEI RD, SUITE 204
HONOLULU, HI, 96817-5318

Company Profile

n/a

Additional Details

Field Value
DUNS: 113226823
Hubzone Owned: N
Socially and Economically Disadvantaged: N
Woman Owned: N
Number of Employees: n/a


  1. Novel Adjuvants to Enhance the Immunogenicity of a Dengue Vaccine

    Amount: $99,888.00

    Dengue virus (DENV) is a mosquito-borne flavivirus that poses a tremendous public health threat throughout the world. The U.S. military has also been challenged by dengue for over a hundred years and ...

    SBIR Phase I 2015 Department of Defense Army
  2. Cross-Protective Multivalent Vaccine for Tick-Borne Flaviviruses

    Amount: $1,156,549.00

    DESCRIPTION provided by applicant The tick borne flavivirus TBFV group includes a number of important human pathogens that result in serious encephalitic or hemorrhagic diseases that are either ...

    SBIR Phase II 2015 Department of Health and Human Services National Institutes of Health
  3. Development of a Recombinant Subunit Vaccine for CCHF

    Amount: $530,899.00

    DESCRIPTION (provided by applicant): Emerging and reemerging infectious diseases continue to pose serious health threats world-wide. Consequently, the development of measures to mitigate the natural, ...

    SBIR Phase I 2012 Department of Health and Human Services
  4. Recombinant Subunit Vaccine For Tick-Borne Encephalitis

    Amount: $2,983,510.00

    DESCRIPTION (provided by applicant): Tick-borne encephalitis (TBE) is a neurological disease caused by Flaviviruses of the tick-borne encephalitis group and causes death in up to 60% of the individua ...

    SBIR Phase II 2009 Department of Health and Human Services
  5. Discovery of West Nile Virus Protease Inhibitors

    Amount: $999,975.00

    DESCRIPTION (provided by applicant): The strain of West Nile virus now endemic in the continental United States is more virulent than the virus originally isolated in Africa and is classified as a cat ...

    SBIR Phase I 2006 Department of Health and Human Services
  6. Structure Based Design of Dengue Virus Fusion Inhibitors

    Amount: $797,650.00

    DESCRIPTION (provided by applicant): Over half of the world population is at risk for infection by dengue virus, a mosquito borne member of the Flavivirus family that consists of four distinct serotyp ...

    SBIR Phase I 2006 Department of Health and Human Services
  7. Optimization of Small Molecule Botulinum Neurotoxin Inhibitors

    Amount: $1,019,210.00

    DESCRIPTION (provided by applicant): Medicinal and computational chemistry methods will be used to optimize validated hit compounds found to inhibit botulinum neurotoxin. These inhibitors, discovered ...

    SBIR Phase I 2006 Department of Health and Human Services
  8. Recombinant Subunit Protein for Flu Vaccine

    Amount: $979,908.00

    DESCRIPTION (provided by applicant): Current influenza vaccine production procedures (use of embryonated chicken eggs) inherently limit the amount of influenza vaccine that can be produced prior to e ...

    SBIR Phase I 2005 Department of Health and Human Services
  9. Recombinant Subunit Vaccine/Prevention of West Nile Vir*

    Amount: $5,046,580.00

    DESCRIPTION (provided by applicant): West Nile virus infection is an emerging infectious disease in the United States. The virus infects birds, which serve as the natural reservoir for the virus, in a ...

    SBIR Phase II 2004 Department of Health and Human Services
  10. Recombinant Subunit Vaccine for Tick-Borne Encephalitis

    Amount: $422,170.00

    DESCRIPTION (provided by applicant): Tick-borne encephalitis (TBE) is a neurological disease caused by Flaviviruses of the tick-borne encephalitis group and causes death in up to 60% of the individua ...

    SBIR Phase I 2004 Department of Health and Human Services

Agency Micro-sites

US Flag An Official Website of the United States Government